Discovery of Novel 4,5-Dihydropyrrolo[3,4-c]pyrazol-6(2H)-one-Based Tubulin Inhibitors Targeting Colchicine Binding Site with Potent Anti-Ovarian Cancer Activity.

IF 6.8 1区 医学 Q1 CHEMISTRY, MEDICINAL
Quanwei Yu,Yujie Liu,Zhijia Wang,Chengyong Wu,Ruofei Zhang,Lun Tan,Lele Zhang,Cuiyu Guo,Lantu Gou,Weimin Li,Yang He,Yuxi Wang
{"title":"Discovery of Novel 4,5-Dihydropyrrolo[3,4-c]pyrazol-6(2H)-one-Based Tubulin Inhibitors Targeting Colchicine Binding Site with Potent Anti-Ovarian Cancer Activity.","authors":"Quanwei Yu,Yujie Liu,Zhijia Wang,Chengyong Wu,Ruofei Zhang,Lun Tan,Lele Zhang,Cuiyu Guo,Lantu Gou,Weimin Li,Yang He,Yuxi Wang","doi":"10.1021/acs.jmedchem.5c00014","DOIUrl":null,"url":null,"abstract":"To address the toxicity of current microtubule inhibitors, we employed the GeminiMol deep learning model to screen the Zinc20 database, identifying a novel 4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one scaffold (Y1) targeting the colchicine binding site. Subsequent optimization culminated in Y60s, a potent antiproliferative agent (SKOV3 IC50 = 0.025 μM) that inhibits clonogenic formation, migration, and invasion of ovarian cancer cells. Y60s inhibited tubulin polymerization which in turn induced G2/M arrest and apoptosis in SKOV3 cells. Y60s demonstrated potent antitumor activity without observable toxicity in an SKOV3 xenograft model. The cocrystal structure of Y8 in complex with tubulin was resolved, confirming the key binding mode of 4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one compounds. This work showcases Y60s as a promising novel tubulin inhibitor and highlights the utility of deep learning model for rapid identification of bioactive compounds from large chemical databases.","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"17 1","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-09-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1021/acs.jmedchem.5c00014","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

Abstract

To address the toxicity of current microtubule inhibitors, we employed the GeminiMol deep learning model to screen the Zinc20 database, identifying a novel 4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one scaffold (Y1) targeting the colchicine binding site. Subsequent optimization culminated in Y60s, a potent antiproliferative agent (SKOV3 IC50 = 0.025 μM) that inhibits clonogenic formation, migration, and invasion of ovarian cancer cells. Y60s inhibited tubulin polymerization which in turn induced G2/M arrest and apoptosis in SKOV3 cells. Y60s demonstrated potent antitumor activity without observable toxicity in an SKOV3 xenograft model. The cocrystal structure of Y8 in complex with tubulin was resolved, confirming the key binding mode of 4,5-dihydropyrrolo[3,4-c]pyrazol-6(2H)-one compounds. This work showcases Y60s as a promising novel tubulin inhibitor and highlights the utility of deep learning model for rapid identification of bioactive compounds from large chemical databases.
靶向秋水仙碱结合位点的新型4,5-二氢吡咯[3,4-c]吡唑-6(2H)- 1基微管蛋白抑制剂的发现及其抗卵巢癌活性。
为了解决当前微管抑制剂的毒性问题,我们使用GeminiMol深度学习模型筛选Zinc20数据库,鉴定出一种新的靶向秋水秋碱结合位点的4,5-二氢吡咯[3,4-c]吡唑-6(2H)- 1支架(Y1)。Y60s是一种有效的抗增殖剂(SKOV3 IC50 = 0.025 μM),可抑制卵巢癌细胞的克隆形成、迁移和侵袭。Y60s抑制微管蛋白聚合,进而诱导SKOV3细胞G2/M阻滞和凋亡。Y60s在SKOV3异种移植瘤模型中显示出强大的抗肿瘤活性,且无明显毒性。对Y8与微管蛋白配合物的共晶结构进行了解析,确定了4,5-二氢吡咯[3,4-c]吡唑-6(2H)- 1化合物的关键结合模式。这项工作展示了y60作为一种有前途的新型微管蛋白抑制剂,并强调了深度学习模型在从大型化学数据库快速识别生物活性化合物方面的实用性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Medicinal Chemistry
Journal of Medicinal Chemistry 医学-医药化学
CiteScore
4.00
自引率
11.00%
发文量
804
审稿时长
1.9 months
期刊介绍: The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents. The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信